Norvir Exclusivity Is Safe; NIH Says "March-In" Test Is Availability, Not Price
This article was originally published in The Pink Sheet Daily
Abbott has met the requirements of the Bayh/Dole Act, NIH declares. "March-in" rights are not the right way to address drug pricing, agency says: that is up to Congress.
You may also be interested in...
KEI vows to continue battle over Bayh-Doyle restrictions after US Commerce Department suggests it may issue regulations to exclude pricing as a basis for requiring companies to license their patents.
NIH will not invoke its “march-in” authority under the Bayh-Dole Act to allow broader access to Norvir patents, Director Francis Collins says in response to a petition.
A poster and print ad for the protease inhibitor combo make the unsubstantiated claim that patients taking Kaletra "can expect to survive and be healthy" for five years, FDA says. Abbott releases six-year Kaletra data at ICAAC conference.